Sbir concept award for a novel delivery approach to transform metastatic pancreatic cancer treatment and prevention
Active Definitive Contract Awarded Last action
- Contract number
- 75N91025C00018
- Awardee
-
Pathcision Medicine, Inc. UEI CK6QRF2GLBT1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,981
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2025 Pre-Solicitation · 75N91024R00013 · Posted Mar 28, 2024
- Contract value 100% obligated
- $299,981.00 Current and potential, with all options
- Completion date 79% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 55 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Watertown, MA 02472, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$54,960 | |
| Original award | $354,941 |
About this award
The National Cancer Institute awarded a $299,981 definitive contract to Pathcision Medicine, Inc. for development of a novel delivery approach to transform metastatic pancreatic cancer treatment and prevention on August 11, 2025, under a total small business set-aside.
This is an SBIR Concept Award supporting research and development of innovative and transformative technologies. The originating solicitation, posted March 28, 2024 with a due date of April 12, 2024, sought proposals from small business concerns for therapeutic or preventative technologies, devices, diagnostic technologies, or digital health tools for the treatment, detection, and diagnosis of pediatric cancers and rare cancers. Proposals required identification of an anticipated product, the clinical problem, and cancer type(s) to be addressed, along with initial proof-of-concept data, enhanced entrepreneurship skills development, and a business model and commercialization plan.
Place of performance is Watertown, MA 02472. The contract carries a firm fixed price and ultimate completion date of February 10, 2027.
Quick answers
Who was awarded contract 75N91025C00018?
75N91025C00018 was awarded to Pathcision Medicine, Inc. by National Cancer Institute (National Institutes of Health) on August 11, 2025.
How much is contract 75N91025C00018 worth?
The government has obligated $299,981 on 75N91025C00018.
Was contract 75N91025C00018 competed?
The extent of competition for 75N91025C00018 was full and open competition after exclusion of sources. The government received 55 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award